Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727848 | 0.85 | SMN1; SMN2 (0.47) | HTTSMN1; SMN2MAPK1GAATBXAS1 | |
| SCHEMBL727417 | 0.79 | SMN1; SMN2 (0.46) | HTTSMN1; SMN2MAPK1GAATBXAS1 | |
| SCHEMBL727667 | 0.76 | NOS1 (0.44) | HTTSMN1; SMN2MAPK1GAATBXAS1 | |
| SCHEMBL5064080 | 0.74 | SMN1; SMN2 (0.50) | HTTSMN1; SMN2MAPK1GAANAMPT | |
| SCHEMBL729321 | 0.73 | CYP19A1 (0.43) | HTTSMN1; SMN2MAPK1GAATBXAS1 | |
| SCHEMBL729312 | 0.71 | SMN1; SMN2 (0.58) | HTTSMN1; SMN2MAPK1GAANAMPT | |
| SCHEMBL5064083 | 0.70 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2MAPK1GAANAMPT | |
| SCHEMBL729143 | 0.70 | SMN1; SMN2 (0.45) | HTTSMN1; SMN2MAPK1GAATBXAS1 | |
| SCHEMBL729141 | 0.70 | MEN1 (0.42) | — | |
| SCHEMBL727963 | 0.70 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2MAPK1GAATBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249402-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO. LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249402-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME | SOST, CTSA, BECN1 | HTT 3532/4885SMN1; SMN2 4065/4885MAPK1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.